1e
19
1
49
2
2
18
1b
1d
18
34
b6
1d
2 29
1d
25
Peter J. O'Dwyer, M.D.
78
b6
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4e
4
3
3
3
2
4
b
1f
4e
Division of Hematology Oncology
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-301
39 3400 Civic Center Blvd
Philadelphia, PA 19104
26
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-301
39 3400 Civic Center Blvd
Philadelphia, PA 19104
2e
Office: 215-662-7606
32 Fax: 215-349-8551
24
97
32 Fax: 215-349-8551
24
Email:
peter.odwyer@uphs.upenn.edu
12
peter.odwyer@uphs.upenn.edu
13
Education:
21 9 M.D. c
4e University of Dublin, Trinity College Dublin, Ireland, 1975.
c
3
3
3
3
8b
Permanent link21 9 M.D. c
4e University of Dublin, Trinity College Dublin, Ireland, 1975.
c
2 29
21
1e
1d
24
2b
29
27
23
12c Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ: Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy. Cancer Chemother Pharmacol 2003 Notes: In Press.
136 Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors. 2003 Notes: In Press.
112 Yao KS, O’Dwyer PJ: Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. Biochem Pharmacol 2003 Notes: In Press.
1dd Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI: Gene expression patterns in epithelial ovarian carcinomas. 2003 Notes: Manuscript submitted.
ca Flaherty KT, O'Dwyer PJ: Phase II trials in oncology. Anticancer Drug Development Guide. Teicher BA (eds.). 2003 Notes: In Press.
df Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy. Drug Resistance Updates 2003 Notes: In Press.
bd O’Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer. Semin Oncol 30(3 Supp 6): 78-87, 2003.
158 Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. 2003 Notes: Manuscript submitted.
12d Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. 2003 Notes: Manuscript submitted.
2c
7
1d
1f
Selected Publications
1cf Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL: Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV. 2003 Notes: Manuscript submitted.12c Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ: Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy. Cancer Chemother Pharmacol 2003 Notes: In Press.
136 Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors. 2003 Notes: In Press.
112 Yao KS, O’Dwyer PJ: Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. Biochem Pharmacol 2003 Notes: In Press.
1dd Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI: Gene expression patterns in epithelial ovarian carcinomas. 2003 Notes: Manuscript submitted.
ca Flaherty KT, O'Dwyer PJ: Phase II trials in oncology. Anticancer Drug Development Guide. Teicher BA (eds.). 2003 Notes: In Press.
df Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy. Drug Resistance Updates 2003 Notes: In Press.
bd O’Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer. Semin Oncol 30(3 Supp 6): 78-87, 2003.
158 Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. 2003 Notes: Manuscript submitted.
12d Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. 2003 Notes: Manuscript submitted.
2c